Multicentric cross-over trial to assess the glycemic profiles on 8 weeks of vildagliptin and sitagliptin treatment, each, in type-2 diabetic patients with a pre-existing cardiovascular disease pre-treated with insulin, using a PROBE-design

Trial Profile

Multicentric cross-over trial to assess the glycemic profiles on 8 weeks of vildagliptin and sitagliptin treatment, each, in type-2 diabetic patients with a pre-existing cardiovascular disease pre-treated with insulin, using a PROBE-design

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Oct 2015

At a glance

  • Drugs Vildagliptin (Primary) ; Insulin; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms CGM-visit
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Sep 2014 According to the European Clinical Trials database record, status changed from active, no longer recruiting to completed.
    • 04 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top